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Abstract
Introduction: Cardiac complications are potentially life-threatening following emergency repair of ruptured
abdominal aortic aneurysms (rAAA). Our objectives were to describe the incidence, risk factors, cardiac outcomes
and mortality associated with elevated cardiac-specific troponin (cTnI) following repair of rAAA. We hypothesized
that early post-operative cTnI elevation (>0.15 mcg/L) in rAAA patients would identify a high-risk subgroup for
cardiovascular complications and adverse outcomes.
Methods: This was a retrospective population-based cohort study of all referrals for emergency repair of rAAA in
central and northern Alberta, from 1 January 2002 to 31 December 2009. Demographic, clinical, physiologic and
laboratory data were extracted, along with cardiac-specific investigations and events in the 72 hours following
rAAA repair.
Results: In total, 55% of patients (n = 77/141) had elevated cTnI, of which 12% (n = 9) had ST segment elevation,
23% (n = 18) had ST segment depression, 5% (n = 4) had other ECG changes, and 61% (n = 47) had no diagnostic
ECG changes. Those with positive cTnI were more likely to have coronary artery disease (45.5% vs. 23.4%, P = 0.01)
and higher Acute Physiology and Chronic Health Evaluation (APACHE) II scores (24.9 vs. 21.4, n = 0.016). cTnI
positive patients were more likely to receive vasoactive support (58.4% vs. 14.1%, P < 0.001), had longer intensive
care unit (ICU) lengths of stay (8 (3 to 11) vs. 4 (2 to 9) days, P = 0.02) and higher adjusted in-hospital mortality
(40.3% vs. 14.1%; OR 4.23; 95% CI, 1.47 to 12.1; P = 0.007).
Conclusions: Elevated cTnI early after rAAA repair is an independent predictor for post-operative complications
and death.
Introduction
Rupture of an abdominal aortic aneurysm (rAAA) is a
life-threatening condition requiring emergency repair.
Open vascular surgical repair, when coupled with the
high prevalence of co-morbid illness in these patients, in
particular cardiovascular disease, can translate into
significant risk for post-operative complications and
morbidity [1].
The development of peri-operative myocardial injury
has prognostic importance for survivors of emergency
rAAA repair. In a small retrospective study of 101 high-
risk rAAA patients surviving to receive operative repair,
31% of early post-operative deaths were attributed to
acute myocardial infarction (AMI) [2]. In addition, a
small retrospective study found that coronary artery dis-
ease (CAD) was the most common late cause of death
in survivors of rAAA repair [3]. These observations
highlight that patients with rAAA have a high preva-
lence of CAD, which may be subclinical. These patients
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are susceptible to myocardial injury, which is associated
with increased morbidity and mortality.
There are numerous biomarkers available for use in
critical illness with the aim of providing incremental
diagnostic and prognostic information and to better
inform decision-making. However, as recently shown in
a review of biomarkers in sepsis, of the 178 biomarkers
identified, many lacked sufficient sensitivity and specifi-
city to be reliably applied in clinical practice [4]. On the
other hand, cardiac-specific troponins are highly unique
to cardiac muscle. Troponin-I (cTnI) and troponin-T
(cTnT) are integral regulatory proteins involved in
actin-myosin interaction to facilitate myocardial contrac-
tion [5]. Accordingly, this has provided an opportunity
to develop highly sensitive and specific quantitative
assays for myocardial necrosis through early detection of
elevated plasma troponin in patients suspected of having
myocardial injury (both approaching 90 to 100% by 6 to
12 hours) [6]. Importantly, while these troponin assays
remain highly sensitive and specific for myocardial
necrosis, they are unable to discriminate the precise
mechanism of myocardial injury [7].
Recently, the VISION study (Vascular Events in Non-
cardiac Surgery Patients Cohort Evaluation) reported an
11.6% incidence of a high-sensitivity cTnT (fourth gen-
eration) ≥0.02 ng/mL in 11.6% of patients aged 45 years
or older within three days of undergoing non-cardiac
surgery. While corresponding electrocardiogram (ECG)
changes suggestive of myocardial ischemia were not
reported, elevated cTnT showed strong independent
association with higher 30-day mortality. Notably; how-
ever, very few patients included in VISION received
emergency major vascular surgery [8]. Two small cohort
studies, both focused on elective AAA repair, found
early post-operative elevations in cardiac-specific cTnI
in 46 and 58%, respectively [9,10]. Most studies to date
have generally been limited in scope, have evaluated
only elective AAA repair and have often focused only
describing biochemical myocardial injury rather than
correlating these data with a post-operative course, car-
diovascular events and outcomes.
We hypothesized that elevated cTnI in the early post-
operative period would be predictive of a more compli-
cated course and less favorable outcome. Our objectives
were: (a) to describe the incidence and pattern of cTnI
elevation after repair of rAAA; (b) to describe the occur-
rence of electrocardiographic (ECG) and echocardio-
graphic (ECHO) evidence of myocardial ischemia and/or
dysfunction after repair of rAAA; (c) to describe the
post-operative clinical course, treatment intensity and
occurrence of cardiac complications after repair of
rAAA; and (d) to describe the short- and long-term mor-
tality associated with elevated cTnI after repair of rAAA.
Materials and methods
The study protocol was approved by the Health
Research Ethics Board at the University of Alberta prior
to commencement. The requirement for written consent
was waived. The reporting of this study follows the
STROBE guideline [11].
Design, setting and participants
This was a retrospective population-based cohort study.
The study was performed in the province of Alberta,
Canada (population approximately 3.7 million in 2009).
In Alberta, there are eight geographical health zones and
two regional referral centers for all major vascular sur-
gery. In the five health zones comprising central and
northern Alberta (population approximately 2.0 million),
all major vascular surgery and all cases of rAAA surviving
to hospital are referred to the Grey Nuns Community
Hospital (GNH). The GNH is a university-affiliated, 347-
bed hospital located in Edmonton, Alberta. The GNH
intensive care unit (ICU) is a closed, eight-bed mixed
medical-surgical unit staffed by dedicated intensivists and
receives approximately 500 admissions annually. All
patients with emergency repair of rAAA are monitored
and supported in the ICU post-operatively. All adult (≥18
years) patients admitted to the GNH with a primary diag-
nosis of rAAA undergoing surgical repair during the
study period were included.
Study protocol
Patients were identified by query of an ICU-specific clini-
cal and/or administrative database (Minimal Data
Set (MDS) database) between 1 January 2002 and 31
December 2009. The MDS database is maintained by the
regional Division of Critical Care Medicine, and routinely
captures demographic, clinical, physiologic and outcome
data on all admissions to the five participating intensive
care units in Edmonton. We extracted data on patient
demographics, ICU admission source, ICU admission
time, post-operative status, co-morbid conditions, primary
ICU admission diagnoses, necessity for mechanical ventila-
tion, vasoactive support, Acute Physiology and Chronic
Health Evaluation (APACHE) II score, ICU and hospital
duration of stay, and ICU, in-hospital and one-year mor-
tality. Individual patient medical records were also interro-
gated for additional laboratory investigation data (that is,
cTnI), details of in-hospital consultations, peri-operative
complications (that is, myocardial infarction, cardiogenic
shock) and operative/anesthesia records (that is, procedure
duration, blood loss, and transfusions) and discharge
summaries.
All patients had routine serial measurement of serum
cardiac-specific troponin I (cTnI) for a minimum of 72
hours post-operatively. cTnI was measured using the
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Beckman-Coulter assay which detects the presence of
cTnI at a threshold concentration of 0.15 mcg/L [12]. Any
cTnI ≥0.15 mcg/L was designated a positive result (TnI+).
Daily ECGs were evaluated for patterns of myocardial
injury. Any bedside echocardiography (ECHO) reports
were reviewed to provide data on left ventricular hypertro-
phy (LVH), systolic function/left ventricular ejection frac-
tion (LVEF), diastolic dysfunction and regional wall
motion abnormalities.
Operational definitions
Patients were said to have a history of coronary artery
disease (CAD) if this was documented in their medical
records. Presence of diabetes mellitus (DM) was defined
by prior documentation in the medical record or by an
admission HbA1c ≥6.5%. Hypertension was diagnosed if
documented in the medical record. ECG-ST segment ele-
vation and depression were defined as a new deviation of
≥1 mm from baseline in limb ECG leads and ≥2 mm in
precordial ECG leads. Congestive heart failure (CHF) was
defined as hypoxemia and radiographic evidence of pul-
monary edema attributed to impaired cardiac function
and/or documentation by the intensivist/cardiologist of
CHF based on clinical evaluation. Cardiogenic shock was
defined as systemic hypotension and/or end organ hypo-
perfusion attributed to inadequate cardiac output after
volume resuscitation and/or the need for inotropic
therapy.
Statistical analysis
The primary exposure of interest was elevation in cTnI in
the first 72 hours post-operatively. The primary outcome
measure was in-hospital mortality. The secondary out-
come measures were ICU and one-year mortality, ICU
and hospital lengths of stay and occurrence of cardiovas-
cular complications. We analyzed univariate associations
between patient variables and outcomes, stratified by cTnI
status (positive or negative). Continuous normally or near
normally distributed data are reported as means with stan-
dard deviations (SD) and compared by Student’s t-test.
Non-normally distributed continuous data are reported as
medians with inter-quartile ranges (IQR) and were com-
pared by Mann Whitney U-test. Categorical variables were
compared using the two-sided Fisher exact test or the
Chi-squared test. A customized, multiple variable logistic
regression model was created, using in-hospital mortality
as the dependent variable, that considered age, pre-existing
coronary artery disease, APACHE II score, intra-operative
blood loss, vasopressor use, post-operative acute kidney
injury (AKI), ECG changes and cTnI as covariates. ECG
changes were omitted from the final model due to signifi-
cant correlation with cTnI. Data are reported as odds
ratios (OR) with 95% confidence intervals (CI). Model cali-
bration and fit were assessed by the area under the
receiver operating characteristic curve (AUC) and the
Hosmer-Lemeshow goodness of fit (GoF) test, respectively.
Crude survival stratified by AKI was assessed graphically
by the Kaplan-Meier product limit estimator and com-
pared with the log-rank test. All statistical analyses were
two-sided and P < 0.05 was considered significant. Statisti-
cal analyses were conducted using Intercooled Stata
Release 11.2 (Stata Corp., College Station, TX, USA).
Results
In total, 141 patients were admitted to the ICU following
rAAA repair. The estimated median (IQR) distance from
the patient’s residence to hospital was 34 km (18 to 149).
Mean (SD) age was 71 (9) years, 85.8% (n = 121) were
male, 79.4% (n = 112) had a smoking history; 35.5% (n =
50) had documented CAD and 20.0% (n = 28) had prior
myocardial infarction (Table 1).
Clinical characteristics of cTnI+ patients
In total, 55% (n = 77) of patients had an elevated cTnI
(cTnI+) in the first 72 hours post-operatively, whereas
45% (n = 64) had no elevation in cTnI (cTnI-) (Table 1).
cTnI+ patients were more likely to have pre-existing
CAD (45.4% vs. 23.4%; OR 2.72; 95% CI, 1.31 to 5.62, P =
0.008), hypertension (77.9% vs. 60.9%; OR 2.26; 95% CI,
1.09 to 4.69, P = 0.04) and to be prescribed beta-blockers
prior to hospital admission (36.3% vs. 17.2%; OR 2.75;
95% CI, 1.25 to 6.04, P = 0.01). Forty-three percent (n =
32) of cTnI+ patients had acute ECG changes consistent
with acute ischemia, compared with none of the cTnI-
patients.
Of those cTnI+ patients, the initial rise occurred within
the 24 hours of operative repair in 59.7% (n = 46), whereas
36.4% (n = 28) occurred in the subsequent 24 hours
(between 24 and 48 hours), and the remaining 5.2% (n =
4) occurred >48 hours following surgery. In cTnI+
patients, the median (IQR) peak value of cTnI was 1.43
mcg/L (0.53 to 3.04). Peak elevation in cTnI occurred on
the first, second or on or after the third post-operative day
in 39.0%, 35.1%, and 26.0%, respectively.
Clinical course
cTnI+ patients had higher APACHE II scores (P = 0.02)
and were more likely to have received post-operative
vasoactive support (58.4% vs. 9.3%; OR 13.6; 95% CI 5.3
to 34.4, P < 0.001). There was a trend for cTnI+ patients
to have lower nadir and greater relative change in intra-
operative hemoglobin compared with cTnI- patients
(Table 1). Post-operative CHF was significantly more
common in cTnI+ patients (41.6% vs. 14.0%; OR 4.35;
95% CI 1.90 to 9.90, P < 0.001) compared with cTnI-
patients (Table 2). Likewise, the occurrence of cardio-
genic shock was more likely in cTnI+ patients (26.0% vs.
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1.6%; OR 22.1; 95% CI 3.63 to ∞, P < 0.001) compared
with cTnI- patients.
Mortality
Intensive care unit, in-hospital and one-year mortality rates
were 21.4% (n = 30), 28.3% (n = 40) and 34.0% (n = 48),
respectively. In-hospital mortality was significantly higher
for cTnI+ as compared with cTnI- patients (40.3% vs.
14.1%; OR 4.11; 95% CI 1.80 to 9.38, P < 0.001) (Table 2).
Likewise, ICU (31.6% vs. 9.4%; OR 4.46; 95% CI 1.73 to
11.4, P = 0.002) and one-year (45.4% vs. 20.3%; OR 3.27;
95% CI 1.54 to 6.90, P = 0.002) mortality rates were
also higher for cTnI+ as compared with cTnI- patients
(Table 2; Figure 1). By univariate analysis, several additional
factors were associated with in-hospital mortality, includ-
ing older age, higher APACHE II score, greater intra-
operative blood loss, need for peri-operative vasoactive
support, acute ECG changes and development of AKI,








Age (mean (SD)) 71(9) 72 (8) 71 (10) 0.74
Male (n, %) 121 (85.8) 67 (87.0) 54 (84.4) 0.83
Co-morbidities
Coronary artery disease (n, %) 50 (35.5) 35 (45.5) 15 (23.4) 0.008
Diabetes mellitus (n, %) 24 (17.0) 17 (22.1) 7 (10.9) 0.12
Previous myocardial infarction (n, %) 28 (20.0) 19 (24.7) 9 (14.1) 0.17
Hypertension (n, %) 99 (70.2) 60 (77.9) 39 (60.9) 0.04
Current smoker (n, %) 67 (47.5) 33 (44.0) 34 (53.1) 0.30
Ever smoked (n, %) 112 (79.4) 58 (75.3) 54 (84.4) 0.26
Medications (prior to admission)
Beta-blocker (n, %) 39 (27.7) 28 (36.4) 11 (17.2) 0.01
Statin (n, %) 42 (29.8) 28 (36.4) 14 (21.9) 0.09
ACE I/ARB (n, %) 46 (32.6) 29 (37.7) 17 (26.6) 0.22
Peri-operative variables
Heart rate (peak) (BPM) (mean (SD)) 110 (20) 113 (19) 107 (21) 0.08
Atrial fibrillation (n, %) 22 (15.6) 19 (25.0) 3 (4.6) 0.001
APACHE II score (mean (SD)) 23.3 (8.4) 24.9 (8.6) 21.4 (8.0) 0.02
Operative time (minute) (mean (SD)) 230 (75) 231 (75) 228 (77) 0.82
EBL (L) (mean (SD)) 3.4 (3.3) 3.6 (3.0) 2.9 (3.6) 0.21
Hgb (g/L) (nadar) (mean (SD)) 83.6 (16.0) 81.6 (15.2) 86.0 (16.7) 0.10
Hgb (g/L) (delta) (mean (SD)) 54.4 (22.9) 57.0 (21.4) 50.8 (24.5) 0.12
Vasoactive therapy (n, %) 54 (38.3) 45 (58.4) 9 (14.0) <0.001
ECG Changes (n, %) 32 (22.7) 32 (43.0) 0 (0) -
Abbreviations: ACE, angiotensin converting enzyme; APACHE, acute physiology and chronic health evaluation; ARB, angiotensin receptor blocker; bpm, beats per
min; EBL, estimated blood loss; Hgb, hemoglobin








Congestive heart failure (n, %) 41 (29.1) 32 (41.6) 9 (14.0) <0.001
Cardiogenic shock (n, %) 21 (14.9) 20 (26.0) 1 (1.6%) <0.001
Acute kidney injury (n, %) 98 (71.0) 61 (82.4) 37 (57.8) 0.002
Renal replacement therapy (n, %) 18 (13.3) 15 (20.6) 3 (4.8) 0.01
LOS (d) hospital (med (IQR)) 12 (8 to 20) 12 (7 to 20) 11 (9 to 19) 0.84
LOS hospital (d) (survivors)* (med (IQR)) 13 (10 to 22) 16 (11 to 24) 12 (9 to 17) 0.02
LOS ICU (d) (med (IQR)) 5 (2 to 11) 8 (3 to 13) 4 (2 to 9) 0.03
LOS ICU (d) (survivors)* (med (IQR)) 7 (3 to 11) 8 (4 to 15) 4 (2 to 9) 0.002
ICU mortality (n, %) 30 (21.4) 24 (31.6) 6 (9.4) 0.01
In-hospital mortality (n, %) 40 (28.3) 31 (40.3) 9 (14.1) <0.001
1-year mortality (n, %) (n = 139) 48 (34.5) 35 (46.7) 13 (20.3) 0.001
*sub-analysis of survivors, total n = 101, troponin (+) n = 46, troponin (-) n = 55. Abbreviations: ICU, intensive care unit; LOS. length of stay.
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CHF or cardiogenic shock in the post-operative period
(Table 3). After adjustment for age, illness severity and
intra-operative blood loss in multi-variable analysis, ele-
vated cTnI remained independently associated with higher
in-hospital death (OR 4.23; 95% CI 1.47 to 12.1; P = 0.007;
AUC 0.87; 95% CI 0.81 to 0.94, GoF, P = 0.79).
There was no association between timing of the first ele-
vated or peak post-operative cTnI and hospital mortality
(Tables 4 and 5). Likewise, there was no significant differ-
ence in median (IQR) peak cTnI between hospital survi-
vors and non-survivors (1.21 (0.49, 3.68) mcg/L vs. 1.43
(0.96, 2.84) mcg/L, P = 0.37). In cTnI+ patients, pre-exist-
ing CAD was associated with a lower in-hospital mortality
compared to those with no CAD (26.4% vs. 52.4%; OR
0.33; 95% CI 0.13 to 0.86, P = 0.03). cTnI+ patients surviv-
ing to discharge also had considerably longer ICU and
hospital lengths of stay compared with cTnI- patients,
respectively (Table 2).
Impact of ECG changes in cTnI+ patients
ECG changes were present in 43.0% (n = 32) of cTnI+
patients. Of those with ECG changes, 28.1% (n = 9) had
ST segment elevation; 56.3% (n = 18) had ST segment
depression; and 12.5% (n = 4) had non-specific ST seg-
ment changes. ECG changes were a modifying factor for
post-operative cardiac complications and mortality. The
incidence of CHF, cardiogenic shock and in-hospital
mortality were significantly higher in cTnI+ patients with
ECG changes, compared to cTnI+ only and cTnI-
patients without ECG changes (Figure 2). In addition, of
cTnI+ patients, the presence of ECG changes were asso-
ciated with a significantly higher odds of death compared
to those with no ECG changes (56.3% vs. 29.3%; OR 3.11;
95% CI 1.19 to 8.11, P = 0.03).
Post-operative investigations associated with cTnI+
In total, only 62.3% (n = 48) of cTnI+ patients were eval-
uated with ECHO. Of these, 54.1% (n = 26) were found
to have an LVEF <60%, 45.8% (n = 22) had regional wall
motion abnormalities, of whom eight had a prior history
of prior myocardial infarction. ECHO evidence of
reduced LVEF was associated with a higher likelihood of
CHF, cardiogenic shock and mortality. Only one patient
underwent multi-gated acquisition scanning (MIBI) after
transfer from the ICU, which did not reveal any regional
reversible ischemia. Only two patients received peri-
operative cardiac catheterization; of which, only one
received percutaneous coronary intervention (PCI), and
both survived to hospital discharge.
Discussion
We performed a retrospective population-based cohort
study of patients undergoing emergency repair of ruptured
AAA to describe the incidence, risk factors and outcomes
associated with early post-operative elevation in cTnI.
Summary of major findings
Elevation in cTnI in the 72 hours post-operative was
common, occurring in 55% of patients, of which the
majority occurred in the first 24 hours. We found that
Figure 1 Crude Kaplan-Meier survival stratified by post-operative cTnI status.
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those patients with pre-existing CAD, hypertension or
treatment with oral beta-blockers to be more likely to
have elevated cTnI. We found cardiovascular complica-
tions, including CHF and cardiogenic shock, to be more
likely in those with elevated cTnI. In addition, we found
that elevated cTnI was independently associated with a
higher risk for in-hospital mortality and longer stays in
both ICU and hospital. Of interest, we found cTnI+
patients with documented pre-existing CAD had a lower
observed in-hospital mortality compared to cTnI+
patients with no history of CAD. We found no associa-
tion between timing of first or peak or absolute value of
elevated cTnI and mortality. Among cTnI+ patients, only
43% had acute ECG changes; however, this subgroup had
a higher risk of complications and mortality. Less than
two-thirds of cTnI+ patients were investigated with echo-
cardiography, but the majority of the echocardiograms
performed demonstrated evidence of myocardial dysfunc-
tion and/or wall motion abnormalities. Finally, very few
patients received further cardiac-specific investigations.
Limitations
We recognize there are limitations with our study. First,
it was a retrospective cohort study and, therefore, is








Age (mean [SD]) 71 (9) 74 (7) 70 (9) 0.01
Male (n, %) 121 (85.8) 34 (85.0) 87 (86.1) >0.999
Co-morbidities
Coronary artery disease (n, %) 50 (35.5) 14 (35.0) 36 (35.6) >0.999
Diabetes mellitus (n, %) 24 (17.0) 11 (27.5) 13 (12.9) 0.07
Previous MI (n, %) 28 (20.0) 8 (20.0) 20 (19.8) >0.999
Hypertension (n, %) 99 (70.2) 31 (77.5) 68 (67.3) 0.32
Current smoker (n, %) 67 (47.5) 16 (40.0) 51 (50.5) 0.35
Ever smoked (n, %) 112 (79.4) 29 (72.5) 83 (82.2) 0.29
Medications (prior to admission)
Beta-blocker (n, %) 39 (27.7) 11 (27.5) 28 (27.7) >0.999
Statin (n, %) 42 (29.8) 14 (35.0) 28 (27.7) 0.51
ACE I/ARB (n, %) 46 (32.6) 17 (42.5) 29 (28.7) 0.17
Peri-operative variables
APACHE II score (mean (SD)) 23.3 (8.4) 30.4 (9.0) 20.5 (6.3) <0.001
Operative time (minute) (mean (SD)) 230 (75) 217 (77) 236 (75) 0.18
EBL (L) (mean (SD)) 3.4 (3.3) 5.0 (5.1) 2.8 (2.1) 0.01
Hgb (g/L) (nadar) (mean (SD)) 83.6 (16.0) 71.8 (16.4) 88.2 (13.4) <0.001
Hgb (g/L) (delta) (mean (SD)) 54.4 (22.9) 62.9 (27.4) 50.9 (19.9) 0.01
Vasoactive therapy (n, %) 54 (38.3) 31 (77.5) 23 (22.3) <0.001
cTnI (+) (n, %) 77 (54.6) 31 (77.5) 46 (45.5) <0.001
Acute ECG changes (n, %) 32 (22.7) 18 (45.0) 14 (13.9) <0.001
In-hospital events
AKI (n, %) 98 (71.0) 35 (92.1) 63 (63.0) 0.001
Cardiogenic shock (n, %) 21 (14.9) 14 (35.5) 7 (6.9) <0.001
CHF in hospital (n, %) 41 (29.1) 19 (47.5) 22 (21.8) 0.006
Abbreviations: ACE, angiotensin converting enzyme; AKI, acute kidney injury; APACHE, acute physiology and chronic health evaluation; ARB, angiotensin receptor
blocker; EBL, estimated blood loss; Hgb, hemoglobin
Table 4 Mortality stratified by post-operative day on which the initial elevation in cTnI was detected









ICU mortality (n, %) 24 (31.6) 14 (30.4) 9 (36.0) 1 (16.7) 0.74
Hospital mortality (n, %) 31 (40.3) 17 (36.9) 12 (48.0) 2 (33.3) 0.67
1-year mortality (n, %) 35 (46.7) 19 (42.2) 14 (58.3) 2 (33.3) 0.40
Abbreviations: ICU, intensive care unit.
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prone to confounding and bias. Second, despite being a
population-based surveillance over several years, our
cohort remained relatively small, resulting in limited sta-
tistical power and susceptibility to errors of chance.
Third, while post-operative cTnI and ECGs were routi-
nely performed, there was no pre-specified protocol for
further cardiac-specific investigations for cTnI+ patients
and these were done at the discretion of the treating
team. Fourth, we recognize our study spans several
years, during which time revision to the cTnI assay may
have been made. Furthermore, we recognize that newer
fifth generation high-sensitivity assays with lower thresh-
olds for detection of myocardial damage will soon be
available for clinical use [5]. It is likely the greater utili-
zation of these next generation assays will contribute to
diagnostic and interpretive challenges for clinicians con-
fronted with positive results in rAAA and other critically
ill patients [13]. Finally, for patients undergoing in-hos-
pital ECHO, we could not confirm whether prior ECHO
had been performed, thus limiting our confidence in the
acute nature of the ECHO findings.
Comparison with prior literature
Prior studies evaluating the prognostic value of ele-
vated post-operative cTnI in major vascular surgery
have primarily focused on elective surgery [14]. Three
prospective cohort studies have suggested post-opera-
tive cTnI elevation confers increased risk for complica-
tions [14-17]. Kim et al. found a 12% incidence of
cTnI elevation (>1.5 mcg/L) within 72 hours of sur-
gery. This was associated with an increased risk for
AMI and dose-response increase in six-month mortal-
ity [15]. Landerberg et al. found 8.7% had a post-
operative cTnI >1.5 mcg/L that likewise portended an
increased risk for AMI and death. However, consistent
with our data, the incidence of post-operative cTnI
elevation in emergency vascular procedures has been
shown to be considerably higher [18]. In an observa-
tional study of 50 surviving patients of emergency
rAAA repair, Tambyraja et al. reported 46% had post-
operative cTnI elevation; and similar to our study, they
found an association with increased mortality and
lengths of stay [10].
Figure 2 Cardiac events and mortality stratified by post-operative cTnI status and ECG changes. Groups differed significantly for mortality
(P < 0.001), CHF (P = 0.004) and cardiogenic shock (P < 0.001).
Table 5 Mortality stratified by post-operative day on which peak cTnI value occurred









ICU mortality (n, %) 24 (31.6) 11 (36.7) 7 (25.9) 6 (30.0) 0.71
Hospital mortality (n, %) 31 (40.3) 12 (40.0) 10 (37.0) 9 (45.0) 0.92
1-year mortality (n, %) 35 (46.7) 14 (48.3) 11 (42.3) 10 (50.0) 0.88
Abbreviations: ICU, intensive care unit.
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Biochemical evidence of myocardial injury (that is, ele-
vated cTnI) should ideally be interpreted in the context of
acute ECG changes consistent with an acute cardiac event.
We found only 43% of our cTnI+ patients had acute ECG
changes. Similarly, Tambyraja et al. reported 47.8% (n =
11/23) of cTnI+ patients had early post-operative acute
ECG changes [10]. These data clearly confirm peri-opera-
tive cTnI evaluation coupled with acute ECG evidence of
myocardial injury is associated with higher risk for compli-
cations and death. However, we have also shown that peri-
operative cTnI “leak” not associated with acute ECG
changes portends greater risk of complications and death
that exceeds those with no cTnI elevation. This finding is
supported by a recent meta-analysis of nine studies show-
ing “isolated cTnI rise” was associated with increased 30-
day mortality; however, the majority of studies included
failed to specifically describe the occurrence of acute ECG
changes [19]. Similarly, in a cohort of 211 high-risk
patients undergoing emergency non-vascular surgery,
Oscarrson et al. found elevated post-operative cTnI, in the
absence of acute ECG changes, was predictive of major
adverse cardiac events and 30-day mortality [18]. The
majority of prevailing literature does not specifically
describe the presence of acute ECG changes in association
with elevated cTnI, or how these ECG findings potentially
modify the post-operative risk of less favorable outcome.
We believe our data extend these findings by suggesting
incremental risk for cTnI elevation coupled with acute
ECG changes over isolated cTnI elevation alone in the
early post-operative period.
Our study confirmed the high prevalence of echocar-
diographic evidence of myocardial dysfunction and/or
wall motion abnormalities in cTnI+ patients. These
ECHO changes are also associated with an increased risk
of complications and mortality. However, perhaps more
importantly, given the increased peri-operative risk con-
ferred by elevated cTnI, less than two in three patients
were evaluated with post-operative ECHO; and fewer still
underwent further cardiac-specific risk stratification. One
major limitation of many prior studies of cTnI in vascular
surgery has been the lack of assessment of myocardial
function and/or description of cardiac-specific investiga-
tions [10,16,20]. We contend the finding of myocardial
dysfunction and/or wall motion abnormalities in associa-
tion with cTnI may represent true type I peri-operative
myocardial infarction that under ideal circumstances
would prompt early cardiac risk stratification and/or car-
diac angiography. Likewise, elevated cTnI after repair of
rAAA may also represent a failed cardiac “stress test” and
serve to unmask previously undiagnosed and/or subclini-
cal CAD. We also believe our data suggest these patients
are at increased risk for cardiac morbidity and should
receive further cardiovascular risk stratification.
Prior studies have not specifically described the post-
operative clinical course (that is, hemodynamic compro-
mise, congestive heart failure) associated with cTnI eleva-
tion [10,14-16]. Similar to prior studies [10], we found an
association between cTnI+ and longer ICU and hospital
stays. However, we were also able to show that cTnI+
patients suffered more complications (that is, congestive
heart failure; cardiogenic shock; acute kidney injury) and
also received greater treatment intensity (that is, vasoactive
support) compared with cTnI- patients.
The risk associated with pre-operative beta-blocker use
is of interest. This is clearly a complex issue and may not
be modifiable in patients who have already taken their
medications at the time of rupture and acute presentation
to medical attention. Whether this associated risk repre-
sented a direct impact of the therapy or acute peri-opera-
tive withdrawal of therapy or whether beta-blockade was
simply a marker of pre-existing CAD is unclear. Peri-
operative beta-blockade does not benefit all patients
undergoing non-cardiac surgery and has been associated
with increased risk for complications and mortality
[21,22]. Marston et al. described (non-significantly) that a
higher proportion of cTnI+ compared with cTnI- patients
were prescribed pre-operative beta-blocker therapy (88.6%
vs. 77.2%, P = 0.18). In the POBBLE trial, peri-operative
allocation to metoprolol during major elective vascular
surgery resulted in a significantly greater utilization of
intraoperative inotropic support; however, occurrence of
major vascular events (approximately one-third) were not
significantly different [20]. Instead, documentation of pre-
operative beta-blocker should alert clinicians to the risk of
increased susceptibility to myocardial injury and/or hemo-
dynamic complications in the early post-operative period.
For those patients who survive repair of rAAA, the ideal
peri-operative management strategies and/or interventions
to mitigate the negative consequences associated with
cTnI+ and optimize clinical outcome remains unknown.
Our data not only confirm the high incidence of elevated
cTnI+ associated with rAAA, but also the surprisingly
high incidence of cardiac events, complications and the
incremental risk of death. Importantly, our data also sug-
gest that many of these patients receive either limited
early investigations and/or suboptimal long-term cardio-
vascular risk stratification. Our findings are similar to the
study by Kim et al., in which all patients with post-opera-
tive acute myocardial infarction were managed medically,
and none underwent coronary angiography within six
months of the event [15]. In elective vascular surgical
populations, in whom the negative prognostic value of iso-
lated elevated cTnI has been more firmly established,
ongoing clinical trials are evaluating early strategies
for possible mitigation of long-term complications [23].
We contend additional research is needed with specific
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focus on the rAAA cohort. Patients with rAAA are unable
to benefit from pre-operative modification of cardiovascu-
lar risk. Research is required to identify which peri-opera-
tive strategies might mitigate the significant complications
associated with postoperative cTnI elevation in this
setting.
Conclusions
In summary, our population-based cohort study of
patients undergoing emergency repair of ruptured AAA
demonstrates a high incidence of early post-operative
cTnI elevation. The cTnI+ cohort suffered a significant
increase in cardiac events, complications and death.
Optimal management of patients with cTnI elevation in
this setting is unknown, and warrants further investiga-
tion to optimize outcomes in this group with signifi-
cantly worse survival and poor prognosis.
Key messages
• Elevated cTnI in the early post-operative period
following rAAA repair was very common; however,
only approximately one-third of patients showed
acute ECG changes.
• Elevated cTnI occurred more commonly in
patients with pre-existing coronary artery disease,
hypertension and those prescribed pre-hospital beta-
blocker therapy.
• Elevated cTnI was associated with greater risk of
post-operative cardiovascular complications, includ-
ing congestive heart failure and cardiogenic shock,
along with higher resource use, and greater short-
term mortality.
• Only two-thirds of patients were investigated with
echocardiography in response to elevated cTnI; how-
ever, in those undergoing ECHO, findings of reduced
ventricular function and wall motion abnormalities
were common.
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